期刊
BIOMARKERS
卷 21, 期 2, 页码 164-167出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/1354750X.2015.1118551
关键词
diabetic nephropathy; podocyte; urinary podocalyxin; Biomarker
资金
- Grants-in-Aid for Scientific Research [16K09229, 26293165] Funding Source: KAKEN
Diabetic nephropathy has dramatically increased worldwide. In this study, we measured urinary podocalyxin in 240 patients with diabetes. The relationship between urinary podocalyxin and clinical parameters and the effects of dipeptidyl peptidase-4 inhibitors (DPP4i) and alpha-glucosidase inhibitor (a-GI) on urinary podocalyxin levels were examined. Urinary podocalyxin levels were significantly higher in patients with microalbuminuria than in those with normoalbuminuria. Urinary podocalyxin levels were also significantly related to albumin-to-creatinine ratio. Neither DPP4i nor alpha-GI ameliorated the increase in urinary podocalyxin levels. Our results indicated that urinary podocalyxin will be not only an early marker but also a treatment target for DN.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据